[go: up one dir, main page]

WO2024049279A3 - Sustained-release microspheres containing leuprolide, injectable preparation comprising same, and preparation method therefor - Google Patents

Sustained-release microspheres containing leuprolide, injectable preparation comprising same, and preparation method therefor Download PDF

Info

Publication number
WO2024049279A3
WO2024049279A3 PCT/KR2023/013112 KR2023013112W WO2024049279A3 WO 2024049279 A3 WO2024049279 A3 WO 2024049279A3 KR 2023013112 W KR2023013112 W KR 2023013112W WO 2024049279 A3 WO2024049279 A3 WO 2024049279A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
leuprolide
sustained
same
method therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/013112
Other languages
French (fr)
Korean (ko)
Other versions
WO2024049279A2 (en
Inventor
이진우
김보연
이주한
설은영
이희용
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G2gbio Inc
Original Assignee
G2gbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020230059471A external-priority patent/KR102742892B1/en
Application filed by G2gbio Inc filed Critical G2gbio Inc
Priority to CN202380076927.0A priority Critical patent/CN120152702A/en
Publication of WO2024049279A2 publication Critical patent/WO2024049279A2/en
Publication of WO2024049279A3 publication Critical patent/WO2024049279A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to sustained-release microspheres containing a high amount of leuprolide, an injectable preparation comprising same, and a preparation method therefor. During administration, leuprolide is released at a sufficient level in an early stage so that effects of leuprolide are exhibited, thereby allowing exposure to a sufficient amount of a drug while inflammatory reactions and the like, which can be problematic during administration, are minimized, and thus the effects of leuprolide can safely be exhibited at least 1 month.
PCT/KR2023/013112 2022-09-01 2023-09-01 Sustained-release microspheres containing leuprolide, injectable preparation comprising same, and preparation method therefor Ceased WO2024049279A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202380076927.0A CN120152702A (en) 2022-09-01 2023-09-01 Sustained-release microspheres containing leuprorelin, injection preparation containing the same, and preparation method thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20220110883 2022-09-01
KR10-2022-0110883 2022-09-01
KR10-2022-0147421 2022-11-07
KR20220147421 2022-11-07
KR10-2023-0059471 2023-05-08
KR1020230059471A KR102742892B1 (en) 2022-09-01 2023-05-08 Sustained release microsphere comprising leuprolide, injection formula comprising the same, and method for preparing the same

Publications (2)

Publication Number Publication Date
WO2024049279A2 WO2024049279A2 (en) 2024-03-07
WO2024049279A3 true WO2024049279A3 (en) 2024-11-07

Family

ID=90098380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/013112 Ceased WO2024049279A2 (en) 2022-09-01 2023-09-01 Sustained-release microspheres containing leuprolide, injectable preparation comprising same, and preparation method therefor

Country Status (2)

Country Link
CN (1) CN120152702A (en)
WO (1) WO2024049279A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087221A1 (en) * 2004-03-15 2005-09-22 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
KR101113044B1 (en) * 2008-08-29 2012-02-27 동국제약 주식회사 Method for manufacturing delayed-release microspheres by solvent intra-exchange evaporation
KR20180131077A (en) * 2017-05-31 2018-12-10 주식회사 대웅제약 Method of preparing sustained release drug microparticles with ease of release control
KR20190023314A (en) * 2017-08-28 2019-03-08 차의과학대학교 산학협력단 Method for manufacturing sustained release microsphere containing leuprolide prepared by electrospraying
KR102386163B1 (en) * 2021-12-03 2022-04-14 (주)인벤티지랩 Microparticles containing leuprolide and manufacturing method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087221A1 (en) * 2004-03-15 2005-09-22 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
KR101113044B1 (en) * 2008-08-29 2012-02-27 동국제약 주식회사 Method for manufacturing delayed-release microspheres by solvent intra-exchange evaporation
KR20180131077A (en) * 2017-05-31 2018-12-10 주식회사 대웅제약 Method of preparing sustained release drug microparticles with ease of release control
KR20190023314A (en) * 2017-08-28 2019-03-08 차의과학대학교 산학협력단 Method for manufacturing sustained release microsphere containing leuprolide prepared by electrospraying
KR102386163B1 (en) * 2021-12-03 2022-04-14 (주)인벤티지랩 Microparticles containing leuprolide and manufacturing method thereof

Also Published As

Publication number Publication date
WO2024049279A2 (en) 2024-03-07
CN120152702A (en) 2025-06-13

Similar Documents

Publication Publication Date Title
EP0069259B1 (en) Prolonged-action form of bromohexine, and process for its preparation
US6117450A (en) Method of making a perorally administered solid drug with controlled effective ingredient delivery
US5439689A (en) Diltiazem formulation
US11723874B2 (en) Delayed release deferiprone tablets and methods of using the same
HK1050487A1 (en) Multiparticulate modified release composition
Speck et al. Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB)
IE921603A1 (en) Diltiazem formulation
WO2024049279A3 (en) Sustained-release microspheres containing leuprolide, injectable preparation comprising same, and preparation method therefor
KR970008157B1 (en) Scheduled Release Tablets Containing Naproxen
KR930702961A (en) Pharmaceutical composition
WO2003057278A2 (en) Drug delivery system for sustained delivery of glipizide
DE69702985T2 (en) Dosage forms containing steroid with a steroid-tight envelope
US4049791A (en) Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents
KR20230152051A (en) FORMULATION OF A MULTILAYERED PELLET COMPRISING MELATONIN
CN112741827A (en) Vigabatrin solid preparation and preparation method thereof
TW202126289A (en) Sustained-release formulation of pregabalin
JPS6045162B2 (en) antidepressants
RU2222318C2 (en) Composition for improving cerebral circulation
Becker et al. Tolerance in Patients with Coronary Heart Disease Under Chronic Treatment with Isosorbide Dinitrate?
WO2002019991A1 (en) Multiparticulate pharmaceutical dosage form and a method for producing the same
CN120053386A (en) Oral preparation containing bevacizidine and statin drugs and preparation process thereof
Sturtevant et al. Studies on the anti-hypertensive action of 2, 3-diarylalkanonitriles
WO2020121234A1 (en) Solid oral pharmaceutical compositions comprising complex monolithic matrices for chronotropic administration of medicaments in the gastrointestinal tract
US20070185180A1 (en) Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
EA042135B1 (en) DEFERIPRONE DELAYED RELEASE TABLET AND METHOD FOR ITS MANUFACTURE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23860954

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202380076927.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202380076927.0

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 23860954

Country of ref document: EP

Kind code of ref document: A2